GlassScriptPhysician profile
Cassandra Burba
NPI 1609410851
$973.30
in general payments reported to CMS, 2019-2025
16 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $474 · 2023: $54.51 · 2024: $28.83 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $367.60 | 2022 | |
| Integra Lifesciences Corporation | $180.34 | 2021-2022 | |
| Baxter Healthcare | $113.10 | 2021 | |
| Motiva USA, LLC | $42.82 | 2025 | |
| Novo Nordisk INC | $42.06 | 2023-2024 | Wegovy |
| Bsn Medical INC | $39.81 | 2022 | |
| Medtronic, INC. | $27.49 | 2023 | Signia |
| Polynovo North America LLC | $23.61 | 2025 | Novosorb Btm |
| Convatec INC. | $20.05 | 2022 | |
| Boston Scientific Corporation | $19.24 | 2025 | Wavewriter Alpha Prime 16 |
| Paratek Pharmaceuticals, INC. | $18.38 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.33 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $17.42 | 2025 | Exparel |
| Bioventus LLC | $15.60 | 2022 | |
| Vivus LLC | $13.79 | 2023 | Qsymia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Burba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.